Name | Type | Posted | Actions |
|---|---|---|---|
RFP 75A50121R00013 Pages 1-2 9-10-2021.pdf | Sep 10, 2021 | ||
Amendment 4 - Summary.pdf | Sep 10, 2021 | ||
RFP SOW-New Stockpile Updated with Responses 9-2-2021.pdf | Sep 3, 2021 | ||
New Email Account 8-29-2021.pdf | Aug 29, 2021 | ||
Amendment 3 - Past Performance Update v1.pdf | Aug 26, 2021 | ||
Amendment 3 - Past Performance Update.pdf | Aug 25, 2021 | ||
Response - Proposal Ext.pdf | Aug 18, 2021 | ||
QA for Follow-On Stockpile - Additional Questions - 8-16-21 FINAL .pdf | Aug 17, 2021 | ||
QA for Follow Stockpile - IDIQ 8-6-21 FINAL.pdf | Aug 7, 2021 | ||
Amendment 2 - Summary.docx | DOCX | Jul 26, 2021 | |
RFP SOW-New Stockpile 6-29-2021 - Amendment 1.pdf | Jul 23, 2021 | ||
Amendment 1 - Summary.pdf | Jul 23, 2021 | ||
RFP SOW-New Stockpile 6-29-2021 - Program Updated - CLEAN.pdf | Jun 29, 2021 |
Acquisition of Medical Countermeasures (MCMs) for Pandemic Influenza and Emerging Diseases Preparedness and Response
Contact and place of performance
Wendell Conyers
DC
USA
Reference Amendment 1 PERIOD OF PERFORMANCE a. The base period of performance of this contract is anticipated for thirty-six (36) monthsfrom date of award. The period of performance may be extended up to 24 months withthe exercise of option(s), structured as CLINs. b. If the Government exercises its option(s), the period of performance will be increased as listed below: Option I Twelve (12) Months (Year 4) Option II...
View moreThe Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA) issued solicitation 75A50121R00013 to acquire medical countermeasures (MCMs) for pandemic influenza and emerging diseases. This requirement is classified under NAICS 325414 Biological Product (except Diagnostic) Manufacturing and PSC 6505 DRUGS AND BIOLOGICALS. The contract features a 36-month base period with two 12-month options and a minimum guarantee of $50,000.00 for the duration of the award. Performance is located in Washington, DC, and responses were due by September 13, 2021.
The scope of work includes the production of cGMP master and working seed lots for inactivated, live attenuated, or recombinant influenza vaccines. Contractors provide research, investigational, and commercial-scale bulk lots, as well as adjuvant bulk products that have completed Phase 2 development. Responsibilities extend to formulation and filling for vials, syringes, and sprayers, as well as storage and stability testing for antigen and adjuvant materials. The solicitation also covers the manufacture of potency reagents, candidate vaccine viruses, and the execution of clinical and non-clinical studies.
Pricing is primarily structured as firm-fixed-price, though specific tasks for shipping, analytical testing, and emerging pathogen activities will be determined via subsequent Requests for Task Order Response (RTOR). The procurement documentation includes 13 attachments, including several amendments and updated Statement of Work files. Wendell Conyers is the designated point of contact for this combined synopsis/solicitation.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.